Tested Applications
| Positive WB detected in | A375 cells |
| Positive IP detected in | A375 cells |
| Positive IHC detected in | human breast cancer tissue, human brain tissue, human gliomas tissue, human liver cancer tissue, human ovary tumor tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
11059-1-AP targets IL-13RA2 in WB, IHC, IF, IP, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag1534 Product name: Recombinant human IL-13RA2 protein Source: e coli.-derived, PKG Tag: GST Domain: 24-330 aa of BC020739 Sequence: SSSDTEIKVNPPQDFEIVDPGYLGYLYLQWQPPLSLDHFKECTVEYELKYRNIGSETWKTIITKNLHYKDGFDLNKGIEAKIHTLLPWQCTNGSEVQSSWAETTYWISPQGIPETKVQDMDCVYYNWQYLLCSWKPGIGVLLDTNYNLFYWYEGLDHALQCVDYIKADGQNIGCRFPYLEASDYKDFYICVNGSSENKPIRSSYFTFQLQNIVKPLPPVYLTFTRESSCEIKLKWSIPLGPIPARCFDYEIEIREDDTTLVTATVENETYTLKTTNETRQLCFVVRSKVNIYCSDDGIWSEWSDKQC Predict reactive species |
| Full Name | interleukin 13 receptor, alpha 2 |
| Calculated Molecular Weight | 380 aa, 44 kDa |
| Observed Molecular Weight | 55-70 kDa |
| GenBank Accession Number | BC020739 |
| Gene Symbol | IL13RA2 |
| Gene ID (NCBI) | 3598 |
| RRID | AB_2124417 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q14627 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
IL13RA2, also named as IL13R and CD213a2, belongs to the type I cytokine receptor family. It binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4). IL13RA2 lacks the cytoplasmic domain for signaling, indicating that it acts as a decoy receptor. IL13RA2 gene polymorphisms have been associated with systemic sclerosis (PMID: 16981293). Overexpression of IL13RA2 gene has been reported in several types of cancer, including melanoma, lung cancer, and brain tumor, which makes it a potential immunotherapeutic target (PMID: 19895199; 24970476; 24021875).
Protocols
| Product Specific Protocols | |
|---|---|
| IHC protocol for IL-13RA2 antibody 11059-1-AP | Download protocol |
| IP protocol for IL-13RA2 antibody 11059-1-AP | Download protocol |
| WB protocol for IL-13RA2 antibody 11059-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
The IL-13RA2 Polyclonal antibody (Cat# 11059-1-AP) has 16 citations across journals including Cell Reports in Medicine, Neuro-Oncology, Cancer Biology & Medicine, Journal of Controlled Release, Clinical Science, Frontiers in Pharmacology, Oncology Reports, Oncology Research, Frontiers in Physiology, Frontiers in Neuroscience, Discovery Oncology, Cancer Reports, Biochemical and Biophysical Research Communications, Journal of Oral Science, and Nanotheranostics. Research fields span oncology (glioblastoma, prostate, thyroid, cervical, NK/T cell lymphoma), cardiovascular disease, diabetes, nephrology, immunology, and neurodevelopment.
| Species | Application | Title |
|---|---|---|
Cell Rep Med EGFR inhibition promotes functional engraftment and graft survival via donor-derived CHI3L1 in fetal RPE suspension transplantation. | ||
Neuro Oncol Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | ||
Cancer Biol Med IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation.
| ||
J Control Release In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma. | ||
Clin Sci (Lond) A new mechanism of arterial calcification in diabetes: interaction between H3K18 lactylation and CHI3L1 | ||
Front Pharmacol Network pharmacology, molecular docking, and experimental verification reveal the mechanism of San-Huang decoction in treating acute kidney injury |





















